Catalyst Pharmaceuticals, Inc.
CPRXDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001369568
Catalyst Pharmaceuticals, Inc. was delisted in 2026; its insiders filed their last Form 4 on Jul 17, 2026; 395 institutions reported holding it in 13F filings for Q2 2026, worth $3.39B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 395
- Q2 2026, +17 vs. previous quarter
- 13F value
- $3.39B
- Reported value at the end of Q2 2026
- Superinvestors holding
- 1
- At the end of Q2 2026
Superinvestors holding CPRX, Q2 2026
1 superinvestor reports holding Catalyst Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
0.1%
Catalyst Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 344,593
- Value
- $10.8M
Latest insider trades
Open-market purchases and sales by Catalyst Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 16, 2025 (view filing) | Dec 12 | 4 days | Harper MollyDirector | SSaleCommon stock, par value $0.001 per share | −26.7K | $23.25 | −$621.9K | −91.9%2.36K after | 3 lots |
| Nov 28, 2025 (view filing) | Nov 26 | 2 days | Del Carmen JeffreyChief Commercial Officer | SSaleCommon Stock, par value $0.001 per share | −11.0K | $23.33 | −$256.2K | −73.5%3.96K after | |
| Nov 14, 2025 (view filing) | Nov 12 | 2 days | Elsbernd BrianChief Compliance/Legal Officer | SSaleCommon Stock, par value $0.001 per share | +40.0K | $22.70 | +$908.0K | +20.9%231.0K after | |
| Sep 10, 2025 (view filing) | Sep 8 | 2 days | Elsbernd BrianChief Compliance/Legal Officer | SSaleCommon Stock, par value $0.001 per share | −30.0K | $20.30 | −$609.0K | −10.0%271.0K after | |
| Sep 5, 2025 (view filing) | Sep 3-4 | 2 days | Elsbernd BrianChief Compliance/Legal Officer | SSaleCommon Stock, par value $0.001 per share | −50.0K | $19.74 | −$987.2K | −21.0%188.6K after | 2 lots |
| Aug 28, 2025 (view filing) | Aug 27 | 1 day | Tierney David SDirector | SSaleCommon Stock, par value $0.001 per share | −26.0K | $20.20 | −$525.2K | −6.4%379.6K after | |
| Aug 28, 2025 (view filing) | Aug 26 | 2 days | Miller SteveChief Op. & Scientific Officer | SSaleCommon stock, par value $0.001 per share | −115.0K | $20.28 | −$2.33M | −10.8%949.7K after | |
| Aug 28, 2025 (view filing) | Aug 26 | 2 days | Daly Richard JPresident and CEO | SSaleCommon stock, par value $0.001 per share | −23.0K | $20.62 | −$473.6K | −9.2%226.8K after | |
| Jun 12, 2025 (view filing) | Jun 10-11 | 2 days | Sundaram PreethiChief Strategy Officer | SSaleCommon Stock, par value $0.001 per share | −3.92K | $26.41 | −$103.6K | −8.7%41.1K after | 2 lots |
| Jun 10, 2025 (view filing) | Jun 6-9 | 4 days | McEnany Patrick JDirector, Other: Chairman of Board of Directors | SSaleCommon Stock, par value $0.001 per share | −200.0K | $26.09 | −$5.22M | −4.5%4.28M after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Catalyst Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 19,158,785 | $602.2M | 0.01% | +384,255+2.0% | Added |
| State Street Corp | 7,627,036 | $239.7M | 0.01% | +763,976+11.1% | Added |
| American Century Companies Inc | 5,553,921 | $174.6M | 0.08% | +1,415,505+34.2% | Added |
| Vanguard Capital Management LLC | 5,135,345 | $161.4M | 0.00% | +12,679+0.2% | Added |
| Dimensional Fund Advisors LP | 3,634,171 | $114.2M | 0.02% | +204,556+6.0% | Added |
| Glazer Capital, LLC | 3,602,865 | $113.2M | 2.79% | +3,602,865 | New |
| JPMorgan Chase & Co | 3,169,902 | $99.9M | 0.01% | +2,703,082+579.0% | Added |
| Geode Capital Management, LLC | 3,150,256 | $99.0M | 0.01% | +177,854+6.0% | Added |
| HBK Investments L P | 2,820,302 | $88.6M | 1.03% | +2,820,302 | New |
| Morgan Stanley | 2,760,358 | $86.8M | 0.00% | +73,059+2.7% | Added |